The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Age and Comorbidity As Independent Prognostic Factors in the Treatment of Non–Small-Cell Lung Cancer: A Review of National Cancer Institute of Canada Clinical Trials Group Trials
Open accessAbstract
Purpose: This study analyzed patients enrolled in two large, prospectively randomized trials of systemic chemotherapy (adjuvant/palliative setting) for non–small-cell lung Cancer (NSCLC). The main objective was to determine if age and/or the burden of chronic medical conditions (comorbidity) are independent predictors of survival, treatment delivery, and toxicity. Patients and Methods: Baseline comorbid conditions were scored using the Charlson comorbidity index (CCI), a validated measure of patient comorbidity that is weighted according to the influence of comorbidity on overall mortality. The CCI score (CCIS) was correlated with demographic data,(ie, age, sex, race), performance status (PS), histology, cancer stage, patient weight, hemoglobin, alkaline phosphatase, lactate dehydrogenase, outcomes of chemotherapy delivery (ie, type, total dose, and dose intensity), survival, and response. Results: A total of 1,255 patients were included in this analysis. The median age was 61 years (range, 34 to 89 years); 34% of patients were elderly (at least 65 years of age); and 31% had comorbid conditions at randomization. Twenty-five percent of patients had a CCIS of 1, whereas 6% had a CCIS of 2 or greater. Elderly patients were more likely to have a CCIS equal to or greater than 1 compared with younger patients (42% v 26%; P < .0001), as were male patients (35% v 21%; P < .0001) and patients with squamous histology (36% v 29%; P = .001). Although age did not influence overall survival, the CCIS appeared prognostic (CCIS 1 v 0; hazard ratio 1.28; 95%CI, 1.09 to 1.5; P = .003). Conclusion: In these large, randomized trials, the presence of comorbid conditions (CCIS ≥ 1), rather than age more than 65 years, was associated with poorer survival.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Charlson, M. E., Pompei, P., Ales, K. L., & MacKenzie, C. R. (1987) · Journal of Chronic Diseases · doi:10.1016/0021-9681(87)90171-8 · Cited by 49,742
Non-small Cell Lung Cancer Collaborative Group (1995) · BMJ · doi:10.1136/bmj.311.7010.899 · Cited by 2,850
Underrepresentation of Patients 65 Years of Age or Older in Cancer-Treatment Trials
Hutchins, L. F., Unger, J. M., Crowley, J. J., Coltman, C. A., & Albain, K. S. (1999) · New England Journal of Medicine · doi:10.1056/nejm199912303412706 · Cited by 2,174
Vinorelbine plus Cisplatin vs. Observation in Resected Non–Small-Cell Lung Cancer
Winton, T., Livingston, R., Johnson, D., Rigas, J., Johnston, M., Butts, C., Cormier, Y., Goss, G., Inculet, R., Vallieres, E., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043623 · Cited by 1,810
Self-citationComorbidity and functional status are independent in older cancer patients.
Extermann, M., Overcash, J., Lyman, G. H., Parr, J., & Balducci, L. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.4.1582 · Cited by 984
Elderly Lung Cancer Vinorelbine Italian Study Group (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.1.66 · Cited by 869
Weir, H. K. (2003) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/djg040 · Cited by 867
Gridelli, C., Perrone, F., Gallo, C., Cigolari, S., Rossi, A., Piantedosi, F., Barbera, S., Ferrau, F., Piazza, E., Rosetti, F., et al. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/95.5.362 · Cited by 781
Cancer burden in the aged: an epidemiologic and demographic overview.
Yancik, R. (1997) · PubMed · Cited by 558
Langer, C. J. (2002) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/94.3.173 · Cited by 502
Cited by
Treatment of Patients With Metastatic Urothelial Cancer “Unfit” for Cisplatin-Based Chemotherapy
Galsky, M. D., Hahn, N. M., Rosenberg, J., Sonpavde, G., Hutson, T., Oh, W. K., Dreicer, R., Vogelzang, N., Sternberg, C. N., Bajorin, D. F., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.34.8433 · Cited by 705
The impact of comorbidity on cancer survival: a review
Sogaard, M., W. Thomsen, R., Bossen, Henrik Toft Sørensen, H., & Nørgaard, M. (2013) · Clinical Epidemiology · doi:10.2147/clep.s47150 · Cited by 603
Sex Disparities in Cancer Mortality and Survival
Cook, M. B., McGlynn, K. A., Devesa, S. S., Freedman, N. D., & Anderson, W. F. (2011) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-11-0246 · Cited by 515
Predictors of Early Death Risk in Older Patients Treated With First-Line Chemotherapy for Cancer
Soubeyran, P., Fonck, M., Blanc-Bisson, C., Blanc, J.-F., Ceccaldi, J., Mertens, C., Imbert, Y., Cany, L., Vogt, L., Dauba, J., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.7442 · Cited by 433
Corre, R., Greillier, L., Le Caër, H., Audigier-Valette, C., Baize, N., Bérard, H., Falchero, L., Monnet, I., Dansin, E., Vergnenègre, A., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.5839 · Cited by 403
Metadata
- Authors
- Asmis, T. R., Ding, K., Seymour, L., Shepherd, F. A., Leighl, N. B., Winton, T. L., Whitehead, M., Spaans, J. N., Graham, B. C., & Goss, G. D.
- Venue
- Journal of Clinical Oncology
- Published
- 2008-01-01
- Volume
- 26
- Issue
- 1
- Pages
- 54-59
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2140238199
- Cited by
- 332
- References
- 27
- FWCI
- 13.54
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Age and Comorbidity As Independent Prognostic Factors in the Treatment of Non–Small-Cell Lung Cancer: A Review of National Cancer Institute of Canada Clinical Trials Group Trials. https://app.cochat.ai/papers/10.1200/jco.2007.12.8322
- The paper
- Asmis, T. R., Ding, K., Seymour, L., Shepherd, F. A., Leighl, N. B., Winton, T. L., Whitehead, M., Spaans, J. N., Graham, B. C., & Goss, G. D. (2008). Age and Comorbidity As Independent Prognostic Factors in the Treatment of Non–Small-Cell Lung Cancer: A Review of National Cancer Institute of Canada Clinical Trials Group Trials. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2007.12.8322
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.